The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...
Novo Nordisk has projected slower growth after Wegovy sales more than doubled, amid competition from Eli Lilly. Though shares rose following improved earnings, concerns linger about U.S. demand.
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.